CDC6 and prostate cancer: In prostate cancer, LiCl participates in the reduction of DNA replication and S-phase cell cycle arrest, by disrupting the interaction of E2F factor with DNA, decreasing the expression of the cell division cycle 6 (cdc6), cyclin A, cyclin E, and cdc25C, which are regulated by E2F [157].